CClinicalTrials.gg
CompletedNCT03402529Updated Jan 18, 2019

Added Value of Contrast Enhanced Spectral Mammography, CESM. A Pilot Study.

An interventional study of Contrast Enhanced Spectral Mammography in Breast Cancer, sponsored by Region Skane. Completed at 1 site in Sweden. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-01-18.

Sponsored by Region Skane · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

Introduction: To avoid unnecessary mastectomies and reoperations a correct size assessment of malignant lesions in breast is required. Sometimes a supplementary MRI is therefore recommended. However, at our unit MRI is not easily available. Contrast enhanced spectral mammography (CESM) has in smaller studies been shown to be equal to MRI regarding sensitivity and specificity. Size assessment using contrast-based modalities as CESM has also been shown to be significantly more accurate than using mammography. Prospective randomized studies using CESM are lacking.

Aim: The aim of the study is to evaluate the added value of CESM in diagnostics of breast cancer and choice of operation; partial mastectomy or mastectomy.

A pilot study of 50 patients will be conducted to prepare for a larger prospective randomized study.

Method: Patients found with breast cancer after diagnostics with mammography, ultrasound and core biopsy, and whom are recommended primary surgery, will be enrolled in the study. A supplementary examination with CESM will be performed. Preoperative extent of the malignant lesions are estimated with each modality and is later compared with the extent measured in post-operative PAD. Data on weight, length, age at menopaus, use of contraceptive pills, HRT or endocrine therapy, breast volume and density is collected, as well as data of diagnosis (ductal or lobular carcinoma), surrounding DCIS, histological grade, ER, PgR, Her2 expression and Ki67 index.

In this pilot study sensitivity and specificity for each modality is calculated. Multivariate analysis will be performed regarding influential factors. Pearson correlation coefficient will be calculated for each modality regarding size assessment of the malignant lesions in comparison with definitive PAD.

02

Conditions studied

  • Breast Cancer

Keywords

  • Contrast Enhanced Spectral Mammography
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patients diagnosed with breast cancer and whom are planned for primary surgery
  • Signed informed consent

Exclusion criteria

Exclusion Criteria:

  • Ongoing pregnancy
  • Ongoing lactation
  • Allergy against iodine contrast
  • Treatment with metformin (against diabetes)
  • Renal failure
  • Hyperthyroidism
  • Severe heart condition
  • Myasthenia gravis
  • Implants
  • Inability to understand study information
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Other
    CESM

    Diagnostic Test: Contrast Enhanced Spectral Mammography

Interventions

  • Diagnostic testContrast Enhanced Spectral Mammography

    Pilot study

05

What researchers measure

Primary outcomes

  1. Number of participants with change of treatment

    Mastectomy instead of partial mastectomy, neo-adjuvant chemotherapy instead of primary surgery

    Time frame: 1 month

Secondary outcomes

  1. size assessment of malignant lesions

    correlation with definitive PAD

    Time frame: 2 months

06

Study locations

1 site
  • Department of Surgery
    Lund, 221 85, Sweden
07

References and documents

Publications

  • Ahsberg K, Gardfjell A, Nimeus E, Rasmussen R, Behmer C, Zackrisson S, Ryden L. Added value of contrast-enhanced mammography (CEM) in staging of malignant breast lesions-a feasibility study. World J Surg Oncol. 2020 May 21;18(1):100. doi: 10.1186/s12957-020-01865-0. PubMed 32438917 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03402529
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Nov 28, 2017
Primary completion
Oct 19, 2018
Completion
Oct 19, 2018
Last update
Jan 18, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion